Ewing’s Sarcoma
Ewing’s Sarcoma strikes predominately
male patients in the 5-25 age range. It
most commonly involves the pelvis,
femur, and tibia; however, it is capable of involving any bone in the
body. This lesion closely resembles
pediatric neuroblastoma that strikes
under the age of five. Also, it is
directly related to the Primitive
Neuroectodermal Tumor (PNET) in that these tumors share the genetic
translocation t(11,22). In a well-understood mechanism, this
translocation encodes the FL-1 gene
that composes homologous RNA pol II
binding sites that place control of cell functions in the hands of the sarc promoter.
These lesions have the radiographic appearance of a centrally lytic lesion that will destroy bone cortex known as “permeative destruction” (Figures #7,8).
Figure
#7
Ewing’s sarcoma
of diaphyseal bone. Note the
destruction of the cortex which ultimately led to a pathologic fracture. |
Figure #8
Ewing’s sarcoma of the midshaft humerus |
As
the cortex is destroyed, the tumor will raise the periosteum creating a “onion
skinning” effect on x-ray that is often accompanied by a “hair
on end” appearance as bone forms along vessels stretched between elevated
periosteum and the underlying bone. The
meta-diaphyseal region is most
commonly involved. Histologically,
this lesion will have small round blue
cells in nests that cluster in rosettes (Figure #6).
|
Figure
#6
Micrograph of a small round blue cell tumor.
In this case the diagnosis was Ewing’s Sarcoma. |
This lesion is known for its ability
to mimick other lesions, most
commonly osteomyelitis. It will share features such as fever,
elevated ESR and white blood cell counts.
Also, necrosis of central regions of the tumor will lead to liquefaction
that will resemble pus but fail to
culture any bacteria.
Treatment of solitary lesion involves local resection and chemotherapy with survival rates at 5 years of
70%. XRT is used only in the case of positive margins at resection as
the tumor is highly radiosensitive
but secondary sarcomas are of great concern while success rates remain high
without its use. Unfortunately, 20% of these lesions will present with
metastases and carry a 30% five-year survival.